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Abstract
Compounds targeting nonstructural (NS) proteins of hepatitis C virus (HCV) demon-
strate clinical promise, suggesting that NS3/NS4a, NS5A, or NS5B inhibitors are poten-
tial components in direct-acting antiviral (DAA) combination therapies. In vitro studies 
revealed dramatic inhibition of viral replication or alteration in subcellular localization 















hepatocellular carcinoma and represents a primary reason for liver transplantation in patients 
with end-stage disease. It is estimated that around 350,000 deaths each year occur worldwide 
as a result of HCV-related liver diseases [1]. Chronic infection with HCV afflicts around 185 
million people which represents 2.8% of the world’s population [2]. Phylogenetically, HCV 
© 2017 The Author(s). Licensee InTech. Distributed under the terms of the Creative Commons Attribut on-
NonCommercial 4.0 License (https://creativecommons.org/l censes/b -nc/4 0/), which permits use, distribution
and reproduction for non-commercial purposes, provided the original is properly cited.
exists as seven distinct genotypes each comprises several subtypes and many quasispecies. 
It was reported that more than 10% of the Egyptian population is infected with HCV, where 
genotype 4 represents >93% of the chronic infections [3]. The development of direct-acting 
antiviral (DAA) agents has dramatically enhanced sustained virological response (SVR) rates 
in genotype 1-infected patients [4]. Although the approval of IFN-free DAA combination 
treatments has been associated with high cure rates, the emergence of resistant HCV variants 
has an important role in treatment failure with DAA therapies.
2. Replication cycle of HCV
Elucidation of intracellular HCV replication has fostered the efforts toward development of 
DAA agents, since in the principle, each step represents a potential target for development 
of new DAA. Viral particles enter the host cell by endocytosis. After the release of HCV RNA 
from the virion, the former has two alternative pathways: (a) translated as (+) RNA strand 
at the rough endoplasmic reticulum into the polyprotein precursor that is cleaved by host 
and viral proteases into mature proteins, where viral proteins, with the help of host cell fac-
tors,  stimulate  the  formation of a membranous web  (MW).  In  the alternative pathway,  (b) 






released by exocytosis [5].
2.1. Direct-acting antiviral agents
The development of DAAs has been progressed  through  the accumulative  information on 
HCV life cycle, improved cell culture technology, and establishment of a robust in vitro viral 
propagation system.
So far, four classes of DAAs targeting three HCV proteins [NS3, NS5A, and NS5B] [nucle-
otide/nucleoside polymerase inhibitors (NPI) and non-nucleotide polymerase inhibitors 
(NNPI)]  are approved  for HCV  treatment  in  several  countries around  the globe as  shown 
in Figure 1. Multiple DAAs target specific HCV-encoded nonstructural proteins leading to 
arrest of viral replication [6], thus achieving higher rates of SVR even in cirrhotic and difficult-
to-treat patients.


















(comprising His57, Asp81, and Ser139) as  in Figure 2. NS3/NS4A inhibitors block the NS3 
catalytic site or inhibit NS3/NS4A interaction, thereby blocking HCV polyprotein cleavage 
[9]. In addition to this direct action, it is worth noting that NS3/NS4A protease has the abil-
ity to block interferon gene expression through the impairment of the retinoic acid-inducible 
gene I (RIG-I) and Toll-like receptor 3 (TLR3) pathways. Therefore, inhibition of NS3/NS4A 
protease restores the interferon expression and TLR3 production. Baseline sequencing analy-
sis for NS3/NS4A region revealed the presence of resistance-associated variants (RAVs) in 
Figure 1. HCV genome and potential drug discovery targets shows the currently approved (particularly in Egypt) protease, 
polymerase, and NS5A inhibitors used as part of a multitargeted approach to HCV treatment.
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patients with HCV genotype  1. Although  their presence did not have  an  impact  on  treat-








protease  inhibitors  is  still  the major  obstacle  facing  their  activities.  The  sequence  analysis 
for NS3 protease of genotype 1a in patients who received the simeprevir regimens detected 






residues are represented as van der Waals spheres.  (cited with permission  from Dr. Ralf Bartenschlager University of 
Heidelberg Department of Infectious Diseases, Molecular Virology, INF 345, 1st. Floor D-69120 Heidelberg Germany).
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a relevant polymorphism Q80K in 19–48% [13].  In vitro studies showed that  this mutation 




recommended to test the presence of this mutation in HCV genotype 1a-infected patients and 





believed to regulate several NS5A functions, including RNA binding and self-interaction [15]. 
NS5A is a promiscuous protein which binds to viral (NS5B and RNA) and host factors includ-




served region among all HCV genotypes and contains the amphipathic membrane-anchoring 
helix and a Zn-binding motif that renders NS5A to exhibit high affinity for HCV RNA.
Nonstructural 5A protein has no enzymatic function, and its ultimate function is not fully 







NS5A inhibitors’ mode of action is simplified in Figure 3. Targett-Adams et al. [16] suggested 
that NS5A inhibitors can change the subcellular localization of the NS5A in the infected cells 
from the endoplasmic reticulum to  lipid droplets. Early proof of  this mechanism was pro-
vided  by  Francis  Chisari  Laboratory  [17],  where  amphipathic  alpha-helical  peptide mim-
icking the amino acid composition of the membrane anchor domain at the amino-terminal 
region of HCV NS5A could change the subcellular localization of NS5A that moved from the 
ER membrane to the lipid droplets.
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HCV genome synthesis (Figure 3) [16, 18]. An additional possible mechanism of inhibition is 






binding of DCV to NS5A dimer is blocked in NS5A RAVs, thus preventing the formation of 
MW at  the ER membrane and  the  subsequent blocking of HCV replication. These  sequels 
provide an explanation for the low susceptibility of HCV mutants to NS5A inhibitors in vitro. 
In phase III clinical trial, the use of combination therapy of NS5A inhibitor (DCV) with (NS3/
NS4A inhibitor) asunaprevir revealed that the presence of double baseline NS5A mutations at 
amino acids L31 and Y93 was associated with low response to the combination therapy [21].
In HCV genotype 1a-infected patients, the baseline NS5A mutations conferred high-level resis-
tance to NS5A inhibitors when treated for 24 weeks. These mutations included H58D, Y93H/
Figure 3. Intracellular trafficking of NS5A protein. Once cleaved out from the polyprotein precursor, NS5A mediates the 
formation of replication complex (RC) that contains host proteins, viral RNA, and nonstructural proteins of HCV. Host 



















[unpublished data]. An in vitro study revealed that replicons containing multiple NS5A 
















not common, therefore reducing their impact on treatment response [26].
5. HCV population, replication fitness, and resistance to NS5A inhibitors
Hepatitis C virus exists in a mixture of related but genetically distinct viral populations 
known  as  viral  quasispecies.  The  relative  distribution  of  viral  population depends  on  the 
replication capacity of each within a given environment. Emergence of quasispecies occurs 
as a result of polymorphism which either enhances or decreases the viral fitness of each qua-
sispecies,  thus  leading  to a  change  in  the quasispecies distribution. Upon DAA treatment, 
viral polymorphisms may confer reduced susceptibility to DAAs. Such polymorphisms may 
be present in a fit viral population, thus leading to outgrowth of this mutant over the wild 





















replication cycle. It has the ability to initiate the de novo synthesis of viral RNA. Structurally, 
the NS5B protein appears as the right-hand shape and is divided into three domains, the palm 
domain which has the active catalytic site and surrounded by the thumb and finger domains 
[28]. The thumb domain contains the allosteric site which regulates the active site (Figure 4).
Inhibitors of this enzyme may bind either to the catalytic site, that is, nucleoside polymerase 
inhibitors (NPI), or to four allosteric sites responsible for the configuration of the protein, that 
is, non-nucleoside polymerase inhibitors (NNPI). Since the sequence of this protein retains 
genetic conservation across the viral genotypes, the rates of resistance to these inhibitors seem 
to be relatively rare [9].
6.1. Nucleoside/nucleotide analogue polymerase inhibitors (NPI)
Nucleoside analogue is administered in as a prodrug to facilitate its adsorption where it is 
activated in the hepatocytes. Several phosphorylation steps are required to convert the nucle-
oside into nucleoside triphosphate, and this step is mediated by the cellular kinases [29]. 
The  insertion of  the nucleoside analogue  into RNA chain  terminates  its  elongation.  It was 
observed that the nucleoside inhibitors showed a high genetic barrier to resistance.




tolerable compared to other polymerase inhibitors.











C316N/C316H/C316F in their baseline samples [29]. In another clinical trial at phases II and III 
where SOF was administered, the mutation S282T was not detected at baseline. An important 





subdomains has been rotated by 180° relative to parts. (cited with permission from Dr. Ralf Bartenschlager University of 
Heidelberg Department of Infectious Diseases, Molecular Virology, INF 345, 1st. Floor D-69120 Heidelberg Germany.)





6.2. Non-nucleoside polymerase inhibitors (NNPI)
The non-nucleosides target the allosteric site of the HCV polymerase. Non-nucleoside poly-
merase inhibitors bind to the non-catalytic site and change the conformational structure nec-
essary for the HCV replication. The antiviral activities of these agents were determined and 
ranged from low to moderate, besides they have a low genetic barrier to resistance and inhibit 
HCV  in  a  genotype-dependent manner. As  a  result  of  the  low genetic  barrier  of NNPI  to 
resistance, these agents have been studied in combination with other DAAs to target several 








titargeted approach can augment the rate of response. Substitutions in NS5A, NS3, and NS5B 

















variants and  leads  to positive selection  for  the resistant variants with  low susceptibility  to 
DAAs. The resistant variants may acquire substitutions rendering them fit and competently 
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replicating. The emergence of  the fitness-associated substitutions may be either preexisted 
naturally  or  acquired by  replication  in  the presence of  the drugs  allowing  the virus  to be 
actively replicating during treatment (breakthrough) or after the end treatment (relapse). 
Luckily, S282T mutation is very rare, and if present it afflicts the replication capacity of HCV, 
thus rendering NS5B inhibitors specific for catalytic site binding, for example, SOF, the most 
effective NS5B  inhibitor. Although S282T was  the first described SOF-associated RAS  [30], 
a couple of treatment emergent substitutions were identified such as L159F and V321A [39, 



















sist >6 months posttreatment such as M28T, Q30R/Q30H, L31V, and Y93R [47]. Since most 
formulations contain NS5A inhibitors, these mutations represent a future challenge to the 
next-generation regimens.
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